
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

June 24, 2003

Date of Report (Date of earliest event reported)

ORAGENICS, INC.

(Exact name of registrant as specified in its charter)

Florida
(State or other jurisdiction
of incorporation)

333-100568
(Commission
File Number)

59-3410522
(IRS Employer
Identification No.)

**12085 Research Drive
Alachua, Florida 32615**
(Address of principal executive offices including zip code)

(386) 418-4018
Registrant's telephone number, including area code

None
(Former name or former address, if changed since last report.)

ITEM 7. FINANCIAL INFORMATION AND EXHIBITS

Exhibit No.	Description
--------------------	--------------------

99.1	Press Release
------	---------------

ITEM 9. REGULATION FD DISCLOSURE

Oragenics, Inc. announced today the completion of its public offering.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 24th day of June, 2003.

ORAGENICS, INC.
(Registrant)

BY: /s/ Mento A. Soponis
Mento A. Soponis
President, Principal Executive Officer and a member of the
Board of Directors.

Oragenics, Inc.
12085 Research Drive
Alachua, Florida 32615

TSX-v: Ora.U

PRESS RELEASE

ORAGENICS COMPLETES INITIAL PUBLIC OFFERING

June 24, 2003: Oragenics, Inc. (the "Company") is pleased to announce the successful completion of its initial public offering on June 24, 2003. The Company, through its agent Haywood Securities Inc. ("Haywood"), sold 2,400,000 units (the "Units") in British Columbia and Alberta at a price of US\$1.25 per Unit (the "Offering") for a total of US\$3 Million. Each Unit consists of one common share, one-half of one non-transferable Series A Warrant and one-half of one non-transferable Series B Warrant. Each whole Series A Warrant is exercisable to acquire one common share for a period of six months from the closing date at a price of US\$2.00 per common share and each whole Series B Warrant is exercisable to acquire one common share for a period of nine months from the closing date at a price of US\$3.00 per common share. The common shares of the Company are expected to be listed for trading on the TSX Venture Exchange effective June 25, 2003, and will trade in US dollars.

In connection with the Offering, the Company paid Haywood a commission of 7.5% of the purchase price per Unit sold, issued to Haywood 100,000 corporate finance shares and issued to Haywood and members of its selling group 500,000 agent's warrants (the "Agent's Warrants"). Each Agent's Warrant entitles the holder to acquire one common share at a price of US\$1.25 per common share for a period of two years from the closing date subject to the Company's right to force conversion in certain instances.

Oragenics is a Florida-based biotechnology company that is developing two technologies licensed from the University of Florida. The first is a replacement therapy for the prevention of tooth decay. The second is a broad spectrum antibiotic called *mutacin* 1140. Both technologies are in the pre-clinical development stage.

ORAGENICS, INC.

/s/ Mento A. Soponis
Mento A. Soponis
President and Chief Executive Officer

For further information, please contact Mento A. Soponis at 386.418.4018 www.oragenics.com

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the contents herein.
